H.C. Wainwright analyst Andrew Fein maintained a Hold rating on United Therapeutics (UTHR) today and set a price target of $85. The company’s shares closed yesterday at $79.24, close to its 52-week low of $74.31.
Fein noted:
“We have adjusted our PE multiple and discount rate in light of our updated view of the risks of UTHR’s clinical programs. As a result, we are lowering our PT to $85/share based on an equally weighted composite of: (a) $87/share, as a 30x multiple of taxed and diluted FY22 GAAP EPS of $5.26 discounted back to and (b) an NPV of $84/ share, discount rate 16%, growth rate -2%.”
According to TipRanks.com, Fein is a 2-star analyst with an average return of 0.2% and a 39.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for United Therapeutics with a $121.71 average price target, representing a 53.6% upside. In a report released today, Jefferies also upgraded the stock to Hold with a $90 price target.
See today’s analyst top recommended stocks >>
Based on United Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $205 million. In comparison, last year the company had a net profit of $173 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.
